Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001415889-25-004105·Compass Therapeutics, Inc.
Schedule 13G ownership disclosure
Compass Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 20454B104
Event date: 2024-12-31
- Filing-level shares
- 8,567,896.00
- Percent of class
- 6.2%
- MPM BioImpact LLC
Shares: 8,567,896.00 · Class: 6.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-004105
- Form type
- SCHEDULE 13G
- Filer
- Compass Therapeutics, Inc.
- CIK
- CIK 1738021
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership